Replies to post #214315 on Biotech Values

[DewDiligence]

NVO—FDA panel endorses Semaglutide by 16-0 vote:

https://uk.reuters.com/article/uk-spain-politics-catalonia/spain-catalonia-standoff-set-to-intensify-as-leaders-take-hard-lines-idUKKBN1CN36R

Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly & Co’s once-weekly Trulicity, which in turn has been taking share from Novo Nordisk’s once-daily Victoza. Novo Nordisk is also developing an oral form of semaglutide.